摘要
目的探讨DC-CIK联合化疗在治疗晚期肾癌患者中的综合应用价值。方法回顾性分析接受化疗的46例晚期肾癌病例,其中21例联合DC-CIK治疗(DC-CIK组),25例仅接受化疗(化疗组)。比较2组间肿瘤生长情况、患者长期生存情况、不良反应发生情况等差异;并对外周血淋巴细胞亚群和细胞因子水平进行检测,比较组间差异。结果DC-CIK组实体瘤近期缓解情况显著优于化疗组;DC-CIK组中位总生存时间为20个月、1年生存率为90.48%,显著高于化疗组的17个月、84.00%,P<0.05。治疗1、3个疗程后DC-CIK组CD3+、CD4+、CD8+比例显著高于化疗组,IL-2、IL-12、IFN-γ含量显著高于化疗组,P<0.05。结论 DC-CIK联合化疗能有效提高晚期肾癌患者的免疫能力,促进IL-2、IL-12、IFN-γ等细胞因子的表达,从而发挥杀死肿瘤细胞、缓解实体瘤、延长患者生存期的功效。
Objective To study the comprehensive application value of DC-CIK combined with chemotherapy for advanced renal cell carcinoma.Methods Retrospective analysis of 46 cases of patients with advanced renal cell carcinoma was conducted,21 cases received DC-CIK therapy(DC-CIK group),25 cases received chemotherapy(chemotherapy group).Tumor growth,long-term survival and adverse reactions of the 2 groups were compared; and the levels of peripheral blood lymphocyte subsets and cytokine of the 2 groups were detected and compared.Results The solid tumor remission in the DC-CIK group was better than that of the chemotherapy group,and the median overall survival time and the 1-year survival rate of the DC-CIK group were respectively 20 months and 90.48%,which were higher than those of the chemotherapy group 17 months,84.00%,P <0.05.After 1,3 courses of treatment,the percentages of CD3 +,CD4 +,CD8 + of the DC-CIK group were higher than that of the chemotherapy group; and the serum levels of IL-2,IL-12,IFN-γ of the DC-CIK group were higher than that of the chemotherapy group,all P < 0.05.Conclusion DC-CIK combined with chemotherapy can effectively improve the immunity of patients with advanced renal cell carcinoma,promote the expression of cytokines such as IL-2,IL-12,IFN-γ and so on,so as to kill tumor cells,relieve solid tumor and improve survival of patients.
出处
《实用癌症杂志》
2015年第4期559-562,共4页
The Practical Journal of Cancer
